CYTEIR THERAPEUTICS INC (CYT) Stock Price, Quote, News and Overview
NASDAQ:CYT - Nasdaq - US23284P1030 - Common Stock - Currency: USD
CYT Quote, Performance and Key Statistics
3.02
-0.07 (-2.27%)
The current stock price of CYT is 3.02 USD. In the past month the price decreased by -2.89%. In the past year, price increased by 81.93%.
CYT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CYT
Company Profile
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company is headquartered in Lexington, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.
Company Info
CYTEIR THERAPEUTICS INC
99 Hayden Avenue, Building B, Suite 450
Lexington MASSACHUSETTS US
CEO: Markus Renschler
Employees: 46
Company Website: https://cyteir.com/
Phone: 18572854140
CYTEIR THERAPEUTICS INC / CYT FAQ
What is the stock price of CYTEIR THERAPEUTICS INC today?
The current stock price of CYT is 3.02 USD. The price decreased by -2.27% in the last trading session.
What is the ticker symbol for CYTEIR THERAPEUTICS INC stock?
The exchange symbol of CYTEIR THERAPEUTICS INC is CYT and it is listed on the Nasdaq exchange.
On which exchange is CYT stock listed?
CYT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYTEIR THERAPEUTICS INC stock?
8 analysts have analysed CYT and the average price target is 3.06 USD. This implies a price increase of 1.32% is expected in the next year compared to the current price of 3.02. Check the CYTEIR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYTEIR THERAPEUTICS INC worth?
CYTEIR THERAPEUTICS INC (CYT) has a market capitalization of 108.72M USD. This makes CYT a Micro Cap stock.
How many employees does CYTEIR THERAPEUTICS INC have?
CYTEIR THERAPEUTICS INC (CYT) currently has 46 employees.
What are the support and resistance levels for CYTEIR THERAPEUTICS INC (CYT) stock?
CYTEIR THERAPEUTICS INC (CYT) has a support level at 3.01 and a resistance level at 3.02. Check the full technical report for a detailed analysis of CYT support and resistance levels.
Should I buy CYTEIR THERAPEUTICS INC (CYT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYT, evaluating the profitability, health, valuation and growth aspects
- CYTEIR THERAPEUTICS INC (CYT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYTEIR THERAPEUTICS INC (CYT) Sales and EPS estimates to see what analysts future expectations are.
- CYTEIR THERAPEUTICS INC (CYT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYTEIR THERAPEUTICS INC (CYT) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYTEIR THERAPEUTICS INC (CYT) Stock Chart to make your own analysis
- CYTEIR THERAPEUTICS INC (CYT) Latest news and press-releases to stay up to date.
Does CYTEIR THERAPEUTICS INC (CYT) stock pay dividends?
CYT does not pay a dividend.
What is the Price/Earnings (PE) ratio of CYTEIR THERAPEUTICS INC (CYT)?
CYTEIR THERAPEUTICS INC (CYT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.3).
CYT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CYT. When comparing the yearly performance of all stocks, CYT is one of the better performing stocks in the market, outperforming 90.36% of all stocks.
CYT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYT. While CYT has a great health rating, there are worries on its profitability.
CYT Financial Highlights
Over the last trailing twelve months CYT reported a non-GAAP Earnings per Share(EPS) of -1.3. The EPS increased by 31.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.35% | ||
| ROE | -26.57% | ||
| Debt/Equity | 0 |
CYT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 45% to CYT. The Buy consensus is the average rating of analysts ratings from 8 analysts.